Translational applications of microRNAs in cancer, and therapeutic implications

Gatta, 2011, Rare cancers are not so rare: the rare cancer burden in Europe, Eur. J. Canc., 47, 2493, 10.1016/j.ejca.2011.08.008 van Rooij, 2012, Developing microRNA therapeutics, Circ. Res., 110, 496, 10.1161/CIRCRESAHA.111.247916 Lee, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y Chen, 2005, MicroRNAs as oncogenes and tumor suppressors, N. Engl. J. Med., 353, 1768, 10.1056/NEJMp058190 Ameres, 2013, Diversifying microRNA sequence and function, Nat. Rev. Mol. Cell Biol., 14, 475, 10.1038/nrm3611 Blondal, 2013, Assessing sample and miRNA profile quality in serum and plasma or other biofluids, Methods, 59, S1, 10.1016/j.ymeth.2012.09.015 Chen, 2008, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res., 18, 997, 10.1038/cr.2008.282 Mráz, 2009, MicroRNA isolation and stability in stored RNA samples, Biochem. Biophys. Res. Commun., 390, 1, 10.1016/j.bbrc.2009.09.061 Babak, 2004, Probing microRNAs with microarrays: tissue specificity and functional inference, RNA, 10, 1813, 10.1261/rna.7119904 Londin, 2015, Analysis of 13 cell types reveals evidence for the expression of numerous novel primate-and tissue-specific microRNAs, Proc. Natl. Acad. Sci., 112, E1106, 10.1073/pnas.1420955112 Pimiento, 2007, Cancer of unknown primary origin: a decade of experience in a community-based hospital, Am. J. Surg., 194, 833, 10.1016/j.amjsurg.2007.08.039 Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 Rosenfeld, 2008, MicroRNAs accurately identify cancer tissue origin, Nat. Biotechnol., 26, 462, 10.1038/nbt1392 Kalimutho, 2011, Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer, J. Gastroenterol., 46, 1391, 10.1007/s00535-011-0456-0 Wu, 2011, Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps, Gut, 239236 Xing, 2010, Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers, Mod. Pathol., 23, 1157, 10.1038/modpathol.2010.111 Roa, 2012, Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer, Clin. Invest. Med., 35, 271, 10.25011/cim.v35i5.18700 Xie, 2010, Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer, Lung cancer, 67, 170, 10.1016/j.lungcan.2009.04.004 Yu, 2010, Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers, Int. J. Cancer., 127, 2870, 10.1002/ijc.25289 Roth, 2010, Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer, Breast Cancer. Res., 12, R90, 10.1186/bcr2766 Zearo, 2014, MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers, BMC Cancer., 14, 200, 10.1186/1471-2407-14-200 [cited 2017 August 22]. Available from: https://www.google.com/patents/US9683264. Ashby J, Flack K, Jimenez LA, Duan Y, Khatib AK, Somlo G, et al. Distribution profiling of circulating microRNAs in serum. Analytical Chemistry.86(18):9343–9349. Montani, 2015, miR-Test: a blood test for lung cancer early detection, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv063 Fondazione, 2014 Nih, 2002, state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”), NIH Consens. State Sci. Statements, 19, 1 Fassnacht, 2016, Management of adrenal incidentalomas: european society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors, Eur. J. Endocrinol., 175, G1, 10.1530/EJE-16-0467 Patel, 2013, MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors, Surgery, 154, 1224, 10.1016/j.surg.2013.06.022 Szabó, 2014, Analysis of circulating microRNAs in adrenocortical tumors, Lab. Invest., 94, 331, 10.1038/labinvest.2013.148 Schütte, 2015, Current biomarkers for hepatocellular carcinoma: surveillance, diagnosis and prediction of prognosis, World J. Hepatol., 7, 139, 10.4254/wjh.v7.i2.139 Mangolini, 2015, Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR, Biomarker Res., 3, 1, 10.1186/s40364-015-0037-0 Calin, 2005, A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia, N. Engl. J. Med., 353, 1793, 10.1056/NEJMoa050995 Ji, 2009, MicroRNA expression, survival, and response to interferon in liver cancer, N. Engl. J. Med., 361, 1437, 10.1056/NEJMoa0901282 Yuan, 2016, Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients, Oncol. Lett., 11, 423, 10.3892/ol.2015.3866 Villaruz, 2015, MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603, Clin. Epigenet., 7, 1, 10.1186/s13148-015-0092-2 Kovalchuk, 2008, Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin, Mol. Canc. Therapeut., 7, 2152, 10.1158/1535-7163.MCT-08-0021 Teo, 2012, The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes, Carcinogenesis, 33, 581, 10.1093/carcin/bgr300 Yu, 2015, MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells, Oncol. Rep., 34, 1845, 10.3892/or.2015.4173 Ma, 2016, Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer, Canc. Gene Ther., 23, 66, 10.1038/cgt.2016.2 Sapre, 2016, A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance, Br. J. Canc., 114, 454, 10.1038/bjc.2015.472 Gourgiotis, 2008, Gallbladder cancer, Am. J. Surg., 196, 252, 10.1016/j.amjsurg.2007.11.011 Kono, 2013, High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma, Oncol. Rep., 30, 17, 10.3892/or.2013.2443 Zhou, 2014, MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2, Int. J. Oncol., 44, 2050, 10.3892/ijo.2014.2360 Zhan, 2016, miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1, Tumour Biol., 37, 10553, 10.1007/s13277-016-4957-6 Yang, 2017, MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer, Tumour Biol., 39, 10.1177/1010428317692249 Qiu, 2014, TGF-beta upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1, Mol. Biosyst., 10, 679, 10.1039/c3mb70479c Ma, 2015, MiR-138 suppresses cell proliferation by targeting Bag-1 in gallbladder carcinoma, PLoS ONE [Electronic Resource], 10, 10.1371/journal.pone.0126499 Lv, 2017, Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma, Eur. Rev. Med. Pharmacol. Sci., 21, 518 Jin, 2014, miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells, Tumour Biol., 35, 1503, 10.1007/s13277-013-1207-z Letelier, 2014, miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer, Int. J. Clin. Exp. Pathol., 7, 1849 Chang, 2013, MiR-20a triggers metastasis of gallbladder carcinoma, J. Hepatol., 59, 518, 10.1016/j.jhep.2013.04.034 Li, 2015, MicroRNA signatures in total peripheral blood of gallbladder cancer patients, Tumour Biol., 36, 6985, 10.1007/s13277-015-3412-4 Ueno, 2014, Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma, Acta Med. Okayama, 68, 23 Pass, 2010, hsa-miR-29c is linked to the prognosis of malignant pleural mesothelioma, Canc. Res., 70, 1916, 10.1158/0008-5472.CAN-09-3993 Matsumoto, 2014, Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component, Med. Oncol., 31, 303, 10.1007/s12032-014-0303-2 Kirschner, 2015, MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma, Mol. Oncol., 9, 715, 10.1016/j.molonc.2014.11.007 Busacca, 2010, MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, Am. J. Respir. Cell Mol. Biol., 42, 312, 10.1165/rcmb.2009-0060OC Kirschner, 2012, Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma, J. Thorac. Oncol., 7, 1184, 10.1097/JTO.0b013e3182572e83 Gee, 2010, Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma, Int. J. Canc., 127, 2859, 10.1002/ijc.25285 Cavalleri, 2017, Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease, PLoS ONE [Electronic Resource], 12, 10.1371/journal.pone.0176680 Cappellesso, 2016, Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology, Canc. Cytol., 124, 28 Benjamin, 2010, A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma, J. Mol. Diagn., 12, 771, 10.2353/jmoldx.2010.090169 Wu, 2015, MicroRNA-205 suppresses the growth of adrenocortical carcinoma SW-13 cells via targeting Bcl-2, Oncol. Rep., 34, 3104, 10.3892/or.2015.4295 Soon, 2009, miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer, Clin. Canc. Res., 15, 7684, 10.1158/1078-0432.CCR-09-1587 Schmitz, 2011, Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours, J. Clin. Pathol., 64, 529, 10.1136/jcp.2010.085621 Patterson, 2011, MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy, Cancer, 117, 1630, 10.1002/cncr.25724 Feinmesser, 2015, Specific MicroRNAs differentiate adrenocortical adenomas from carcinomas and correlate with weiss histopathologic system, Appl. Immunohistochem. Mol. Morphol., 23, 522, 10.1097/PAI.0000000000000117 Santarpia, 2013, A miRNA signature associated with human metastatic medullary thyroid carcinoma, Endocr. Relat. Canc., 20, 809, 10.1530/ERC-13-0357 Pennelli, 2015, The PDCD4/miR-21 pathway in medullary thyroid carcinoma, Hum. Pathol., 46, 50, 10.1016/j.humpath.2014.09.006 Mian, 2012, MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome, Thyroid, 22, 890, 10.1089/thy.2012.0045 Abraham, 2011, MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets, Clin. Canc. Res., 17, 4772, 10.1158/1078-0432.CCR-11-0242 Corbetta, 2010, Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue, Endocr. Relat. Canc., 17, 135, 10.1677/ERC-09-0134 Rahbari, 2011, Identification of differentially expressed microRNA in parathyroid tumors, Ann. Surg Oncol., 18, 1158, 10.1245/s10434-010-1359-7 Tay, 2015, Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells, Adv. Drug Deliv. Rev., 81, 117, 10.1016/j.addr.2014.05.010 Ma, 2014, MicroRNA sponge blocks the tumor-suppressing functions of microRNA-122 in human hepatoma and osteosarcoma cells, Oncol. Rep., 32, 2744, 10.3892/or.2014.3517 Luna, 2015, Hepatitis C virus RNA functionally sequesters miR-122, Cell, 160, 1099, 10.1016/j.cell.2015.02.025 Wierzbicki, 2016, Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia, Expet Opin. Biol. Ther., 16, 1125, 10.1080/14712598.2016.1196182 Moshiri, 2014, Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma, Gastroenterol. Hepatol. bed to bench, 7, 43 Yingchoncharoen, 2016, Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come, Pharmacol. Rev., 68, 701, 10.1124/pr.115.012070 Martin, 2016, In vivo localization of miR-34 delivered via liposomal MRX34: chromogenic in situ hybridization (CISH) results in a preclinical model and liver biopsies from phase I patients, ASCO Annu. Meet. Proc., 34 Kota, 2009, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model, Cell, 137, 1005, 10.1016/j.cell.2009.04.021 Luo, 2015, Adeno-associated virus-mediated cancer gene therapy: current status, Canc. Lett., 356, 347, 10.1016/j.canlet.2014.10.045 Trang, 2010, Regression of murine lung tumors by the let-7 microRNA, Oncogene, 29, 1580, 10.1038/onc.2009.445 Xie, 2012, Long-term, efficient inhibition of microRNA function in mice using rAAV vectors, Nature methods, 9, 403, 10.1038/nmeth.1903 MacDiarmid, 2007, Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics, Canc. Cell, 11, 431, 10.1016/j.ccr.2007.03.012 Glover, 2015, microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma, Oncotarget, 6, 36675, 10.18632/oncotarget.5383 Reid, 2015, Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy, Canc. Res., 75, 3976, 10.1158/1538-7445.AM2015-3976 van Zandwijk, 2017, Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, Lancet Oncol., 18, 1386, 10.1016/S1470-2045(17)30621-6 Kao, 2015, A significant metabolic and radiological response after a novel targeted MicroRNA-based treatment approach in malignant pleural mesothelioma, Am. J. Respir. Crit. Care Med., 191, 1467, 10.1164/rccm.201503-0461LE Zhao, 2015, Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression, Biomed. Pharmacother., 75, 142, 10.1016/j.biopha.2015.07.015 Dong, 2001, Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer, Prostate, 49, 166, 10.1002/pros.1131 Bonci, 2008, The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities, Nat. Med., 14, 1271, 10.1038/nm.1880